Scientists at Duke University School of Medicine have identified the molecular mechanism by which prostate cancer cells hide from the immune system, and developed a tool to reverse it, according to research published in Nature Biomedical Engineering on June 16, 2026. The findings provide one of the most specific molecular explanations yet for why prostate cancer is so consistently resistant to the checkpoint inhibitor immunotherapy drugs that have transformed treatment in melanoma, lung cancer, and bladder cancer.
The study was led by researchers from Duke and identified a protein called SPSB1 as a central driver of prostate cancer's immune evasion. When SPSB1 protein levels are elevated, it suppresses production of a molecular flag called MHC-I, which sits on the surface of cells and signals to immune T cells that something is wrong inside. Without sufficient MHC-I, immune cells cannot see the tumor, and immunotherapy drugs designed to remove brakes on T cell activity have nothing to target.
Why This Matters
Prostate cancer is the second most common cancer in American men, affecting more than 300,000 new patients per year in the United States. Most prostate cancers are treated successfully with surgery, radiation, or hormone therapy at early stages. But metastatic prostate cancer, particularly castrate-resistant disease that progresses despite hormone deprivation, remains difficult to treat and carries significant mortality.
Immunotherapy checkpoint inhibitors, drugs like pembrolizumab and nivolumab that have extended survival in numerous other cancer types, have been strikingly ineffective in most prostate cancers. Prostate tumors are described by oncologists as "immune cold," meaning they contain few T cells capable of attacking cancer and fail to attract immune activity. The Duke study provides a direct mechanistic answer for why: SPSB1 protein actively suppresses the cellular flag that would otherwise call T cells to the scene.
What We Know So Far
The Duke team, led by corresponding author Qianben Wang and colleagues, discovered that SPSB1 promotes shortened versions of messenger RNA transcripts for MHC-I components, resulting in reduced MHC-I protein on the tumor cell surface. In the absence of MHC-I, T cells have no signal to respond to, and the tumor becomes effectively invisible to immune surveillance.
To reverse this evasion, the researchers designed a first-of-its-kind RNA-based therapy using a CRISPR-Cas13 system, a tool that binds to rather than cuts RNA. Rather than deleting the SPSB1 gene, the system was engineered to change the length of the SPSB1 mRNA transcript, restoring production of full-length MHC-I molecules on the tumor cell surface. When the therapy was applied to prostate cancer cells in laboratory models, immune T cells regained their ability to identify and attack the tumor cells, converting what had been an immune-cold tumor into an immune-responsive one.
According to MedicalXpress coverage of the study, the research team believes the approach will be difficult for cancer cells to evade because it targets a fundamental RNA processing mechanism, not a single gene that the tumor can simply mutate away from. "It won't be able to evolve fast enough," one researcher told the outlet.
Where the Impact Is Highest
Metastatic castrate-resistant prostate cancer centers at major academic medical institutions including Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, MD Anderson, Memorial Sloan Kettering, and the Duke Cancer Institute will be the earliest settings for any translational work arising from this discovery. Black men in the United States are diagnosed with prostate cancer at roughly 75 percent higher rates than white men and are approximately twice as likely to die from the disease, making the need for effective therapies in this population especially urgent.
What Doctors and Experts Say
The research team's framing of SPSB1 as a master regulator of immune evasion in prostate cancer is significant because it suggests a single molecular target might explain the broad immune-cold phenotype of these tumors, rather than a patchwork of independent evasion mechanisms. The Cas13-based RNA approach, described in SciTechDaily's coverage, addresses immune evasion at the RNA level rather than through DNA editing, a meaningful distinction for clinical development because RNA-based interventions can be more precisely targeted and potentially safer to adjust or reverse.
The research was funded by the National Cancer Institute at the National Institutes of Health, providing governmental validation of the scientific priority of this direction.
What the Evidence Shows and What It Does Not
This is a laboratory and preclinical study published in peer-reviewed Nature Biomedical Engineering on June 16, 2026 (DOI: 10.1038/s41551-026-01720-9), led by Duke University researchers. The study identified SPSB1 as a regulator of MHC-I expression in prostate cancer cells and demonstrated that an RNA-based CRISPR-Cas13 system targeting SPSB1 mRNA restored MHC-I surface expression and immune T cell recognition in cell culture and laboratory models.
What the study did not prove is that the approach is safe or effective in humans. Clinical development of RNA-based cancer therapies is an active and growing field, but no CRISPR-Cas13 therapy has yet received FDA approval for any cancer. Translation from laboratory success to clinical application typically requires years of additional safety, pharmacology, and efficacy studies. Readers should know that this is a mechanistic discovery study with strong therapeutic implications, not an announcement of an available treatment.
Who Faces the Greatest Risk
Men with metastatic castrate-resistant prostate cancer who have progressed on or are ineligible for hormone therapy, chemotherapy, and approved targeted agents face the most immediate need for new treatment approaches. The subset of prostate cancer patients with deficient DNA mismatch repair, approximately 2 to 5 percent of metastatic cases, are the only prostate cancer patients who currently show meaningful response to checkpoint inhibitor immunotherapy. For the remaining 95 to 98 percent, immune evasion mechanisms like the one identified in this study are the primary barrier to immunotherapy benefit.
Symptoms and Warning Signs to Watch For
Metastatic prostate cancer symptoms can include new or worsening bone pain, particularly in the back, hips, or pelvis; unexpected weight loss, fatigue, difficulty urinating; blood in urine; and neurological symptoms if the disease has spread to the spine. Men experiencing any of these symptoms, particularly those with a prior prostate cancer diagnosis, should seek prompt medical evaluation. For men over 50 or those with a family history of prostate cancer, regular PSA screening discussions with a physician are appropriate regardless of symptoms.
What You Can Do Now
Men currently being treated for advanced prostate cancer should ask their oncologist whether genomic profiling of their tumor has been performed, specifically looking for mismatch repair deficiency, which currently predicts response to pembrolizumab. They can also ask whether their cancer center has any open clinical trials testing novel immunotherapy combinations. The SPSB1 finding is too new for clinical trials, but it is consistent with a broader category of research into immune-sensitizing strategies for prostate cancer that is already being tested in clinical settings.
Cost and Access: What Patients Should Know
Current approved immunotherapy for prostate cancer is limited to pembrolizumab for mismatch repair-deficient disease. Sipuleucel-T (Provenge), an approved cancer vaccine for asymptomatic or minimally symptomatic metastatic castrate-resistant prostate cancer, offers a modest survival benefit and is covered by Medicare and most insurers for eligible patients. Patients seeking access to experimental immunotherapy combinations should inquire about clinical trials through the NCI and major cancer centers.
What Happens Next
The Duke team is expected to advance the CRISPR-Cas13 SPSB1 approach through additional preclinical validation, including in vivo tumor models, before any clinical trial application can be made. The identification of SPSB1 as a druggable target will also stimulate interest in small molecule inhibitors of this protein as an alternative to RNA-based approaches. MedicalDaily will report on preclinical and clinical development milestones for this approach as they occur.
The Bottom Line
Duke University scientists have identified the protein responsible for making prostate tumors invisible to the immune system and developed a laboratory approach to reverse it. For a cancer that has consistently failed to respond to the checkpoint inhibitor drugs that have extended life in many other cancers, this mechanistic discovery provides both a specific target and a proof-of-concept intervention. The research is preclinical, but the clarity of the molecular mechanism and the novelty of the RNA-based solution make it a significant advance in the effort to make prostate cancer immunotherapy work.
